Literature DB >> 12116178

Wolfram syndrome: identification of a phenotypic and genotypic variant from Jordan.

Kamel Ajlouni1, Nadim Jarrah, Mohammed El-Khateeb, Mohamed El-Zaheri, Hatem El Shanti, Andrew Lidral.   

Abstract

Wolfram syndrome is an autosomal recessive disorder with probable locus heterogeneity. Only insulin-dependent diabetes mellitus and progressive optic-nerve atrophy are necessary to make the diagnosis, but associated findings include diabetes insipidus, sensorineural hearing loss, ataxia, peripheral neuropathy, urinary-tract atony, and psychiatric illnesses. We performed clinical and molecular studies on four consanguineous families with 16 affected individuals. We point out a new phenotypic variant with absent diabetes insipidus, presence of peptic ulcer disease and bleeding tendency secondary to a platelet aggregation defect. The same phenotypic variant turned out to be a genotypic variant with linkage to a second Wolfram syndrome locus (WFS2) on chromosome 4q22-24. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12116178     DOI: 10.1002/ajmg.10345

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  10 in total

1.  Wolfram syndrome: clinical and genetic profiling of a cohort from a tertiary care centre with characterization of the primary gonadal failure.

Authors:  Liza Das; Ashutosh Rai; Ravimohan Mavuduru; Kim Vaiphei; Akhilesh Sharma; Vishali Gupta; Sanjay Kumar Bhadada; Sailesh Lodha; Naresh Panda; Anil Bhansali; Paramjeet Singh; Pinaki Dutta
Journal:  Endocrine       Date:  2020-04-29       Impact factor: 3.633

Review 2.  Optic atrophies in metabolic disorders.

Authors:  Marjan Huizing; Brian P Brooks; Yair Anikster
Journal:  Mol Genet Metab       Date:  2005-09-27       Impact factor: 4.797

3.  Disrupting CISD2 function in cancer cells primarily impacts mitochondrial labile iron levels and triggers TXNIP expression.

Authors:  Ola Karmi; Yang-Sung Sohn; Sara I Zandalinas; Linda Rowland; Skylar D King; Rachel Nechushtai; Ron Mittler
Journal:  Free Radic Biol Med       Date:  2021-09-20       Impact factor: 7.376

4.  Unique three-site compound heterozygous mutation in the WFS1 gene in Wolfram syndrome.

Authors:  Ziyu Ren; Jixiu Yi; Min Zhong; Yunting Wang; Qicong Liu; Xuan Wang; Dongfang Liu; Wei Ren
Journal:  BMC Endocr Disord       Date:  2021-08-17       Impact factor: 2.763

5.  Clinical approach to optic neuropathies.

Authors:  Raed Behbehani
Journal:  Clin Ophthalmol       Date:  2007-09

6.  A homozygous mutation in a novel zinc-finger protein, ERIS, is responsible for Wolfram syndrome 2.

Authors:  Sami Amr; Cindy Heisey; Min Zhang; Xia-Juan Xia; Kathryn H Shows; Kamel Ajlouni; Arti Pandya; Leslie S Satin; Hatem El-Shanti; Rita Shiang
Journal:  Am J Hum Genet       Date:  2007-08-20       Impact factor: 11.025

Review 7.  Clinical Spectrum Associated with Wolfram Syndrome Type 1 and Type 2: A Review on Genotype-Phenotype Correlations.

Authors:  Maurizio Delvecchio; Matteo Iacoviello; Antonino Pantaleo; Nicoletta Resta
Journal:  Int J Environ Res Public Health       Date:  2021-04-30       Impact factor: 3.390

8.  A novel CISD2 intragenic deletion, optic neuropathy and platelet aggregation defect in Wolfram syndrome type 2.

Authors:  Enza Mozzillo; Maurizio Delvecchio; Massimo Carella; Elvira Grandone; Pietro Palumbo; Alessandro Salina; Concetta Aloi; Pietro Buono; Antonella Izzo; Giuseppe D'Annunzio; Gennaro Vecchione; Ada Orrico; Rita Genesio; Francesca Simonelli; Adriana Franzese
Journal:  BMC Med Genet       Date:  2014-07-24       Impact factor: 2.103

Review 9.  Wolfram Syndrome: Diagnosis, Management, and Treatment.

Authors:  Fumihiko Urano
Journal:  Curr Diab Rep       Date:  2016-01       Impact factor: 4.810

Review 10.  Wolfram Syndrome Type 2: A Systematic Review of a Not Easily Identifiable Clinical Spectrum.

Authors:  Francesco Maria Rosanio; Francesca Di Candia; Luisa Occhiati; Ludovica Fedi; Francesco Paolo Malvone; Davide Fortunato Foschini; Adriana Franzese; Enza Mozzillo
Journal:  Int J Environ Res Public Health       Date:  2022-01-12       Impact factor: 3.390

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.